References
- Weeke, E. R. (1987). Epidemiology of hayfever and perennial allergic rhinitis. Monogr. Allergy, 21, 1–20.
- Abelson, M. B. and Schaeffer, K. (1993). Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv. Ophthalmol., 38 (Suppl), 115–132.
- Ciprandi, G., Buscaglia, S. and Canonica, G. W. (1996). Management of allergic conjunctivitis. Clin. Immunother., 5, 374–391.
- Davies, B. H. and Mullins, J. (1993). Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy, 48, 519–524.
- Bahmer, F. A. (1995). Topical levocabastine — an effective alternative to oral antihistamines in seasonal allergic rhinoconjunctivitis. Clin. Exp. Allergy, 25, 220–227.
- McTavish, D. and Sorkin, E. M. (1989). Azelastine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs, 38, 778–800.
- Ciprandi, G., Pronzato, C., Passalacqua, G., Ricca, V, Bagnasco, M., Grogen, J., Mela, G. S. and Canonica, G. W. (1996). Topical azelastine reduces eosinophil activation and intercellular adhesion molecule- 1-expression on nasal epithelial cells: An anti-allergic activity. J. Allergy Clin. Immunol., 98, 1088–1096.
- Pronzato, C., Ricca, V., Varese, P., Trafelli, T., Bertolini, C., Ciprandi, G. and Canonica, G. W. (1995). Evaluation of anti-allergic activity of azelastine nasal spray. Allergy, 50, 69–71.
- McNeely, W. and Wiseman, L. R. (1998). Intranasal Azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs, 56(1), 91–114.
- Kube, T., Weinberger, A. W. A., Wolf, S. and Schmidt, B. (2000). Clinical trial to investigate the influence of azelastine eye drops on the accommodative capacity in healthy volunteers. Allergy, 55 (Suppl 63), p. 194 (No. 688).
- Van Wijk, R. (1995). Treatment of allergic rhinoconjunctivitis: a review of the role of topical levocabastine. Mediators Inflamm., 4, S31–S38.
- Abelson, M. B. and Weintraub, D. (1994). Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Eur. J. Ophthalmol., 4, 91–101.
- Mösges, R., Spaeth, J. and Klimek, L. (1995). Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis. Mediators Inflamm., 4, S11–S15.
- Dechant, K. L. and Goa, K. L. (1991). Levocabastine. A review of its pharmaceutical properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs, 41, 202–224.
- Ciprandi, G., Buscaglia, S., Catrullo, A., Pesce, G., Fiorno, N., Montagna, P., Bagnasco, M. and Canonica, G. W. (1997). Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert antiallergic activity. Clin. Exp. Allergy, 27, 182–191.
- Giede-Tuch, C., Westhoff, M. and Zarth, A. (1998). Azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Allergy, 53, 857–862.
- Lenhard, G., Mivsek-Music, E., Perrin-Fayolle, M., Obtulowicz, K. and Secchi, A. (1997). Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Curr. Med. Res. Opin., 14(1), 21–28.
- Leino, M., Ennevaara, K., Latvala, A.-L., Nordgren, P., Posti, A.-M., Surves, R. and Takalo, E. (1992). Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clin. Exp. Allergy, 22, 929–932.
- Howarth, P. H. (1995). A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management. Mediators Infiamm., 4, 526–S30.